{
    "2020-04-03": [
        [
            {
                "time": "",
                "original_text": "民生医药|年报点评】天坛生物：产能利用率提升毛利率提高，成都蓉生本部产能将如期释放",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "产能利用率",
                        "毛利率",
                        "成都蓉生",
                        "产能释放"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【天坛生物|年报点评】产能释放叠加产品拓展，规模效应有望逐步体现【安信医药马帅团队】",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "产能释放",
                        "产品拓展",
                        "规模效应"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}